



PROGRAM BOOK

SAVE THE DATE!



10TH ANNUAL

Cardiometabolic Health Congress

October 21 - 24, 2015 • Boston, MA

WELCOME!

Welcome to the 9th Annual Cardiometabolic Health Congress (CMHC). We are pleased you have joined us, our world-renowned expert faculty, 44 prestigious medical associations, and your peers to combat the global health crisis emanating from cardiovascular and metabolic disease.

It is impossible to separate cardiovascular from metabolic disease when it comes to risk assessment, prevention, and clinical intervention. No other conference addresses the breadth and depth of this new paradigm like the CMHC – translating the most current clinical information into real-world solutions that will undoubtedly make a significant impact on your daily practice. And don't forget to visit **CMHC-online.com** for presentation highlights, videos, and online CME activities to supplement the live sessions and stay abreast of the most current educational information throughout the year.

Enclosed you will find the CMHC schedule-at-a-glance and detailed agenda, as well as information on our distinguished faculty and CME symposia. Should you require assistance during your stay, please do not hesitate to visit the CMHC Registration Desk located on the Second Floor of the Sheraton Boston Hotel.

Enjoy your stay in Boston!



George L. Bakris

George L. Bakris, MD
University of Chicago
Pritzker School of Medicine



Christie M. Ballantyne

Christie M. Ballantyne, MD
Methodist DeBakey Heart Center
Baylor College of Medicine



Robert H. Eckel

Robert H. Eckel, MD
University of Colorado
Anschutz Medical Campus



Jay S. Skyler

Jay S. Skyler, MD, MACP
University of Miami
Miller School of Medicine



TABLE OF CONTENTS

Chairpersons Welcome Letter	3
Accreditation Information	4
Learning Objectives	5
Schedule at-a-Glance	6
Agenda	7-11
Chairpersons	12-13
Distinguished Faculty	14-26
Notes	26-27

CMHC ACCREDITATION

Credits listed below are for the entire Cardiometabolic Health Congress. Please see page 5 for details on how to claim CME/CE credits.

Physician Credit

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medical Education Resources and HealthScience Media, Inc. Medical Education Resources is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this live activity for a maximum of 27.5 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP (American Academy of Family Physicians) Credit

This Live activity, Cardiometabolic Health Congress, with a beginning date of 10/22/2014, has been reviewed and is acceptable for up to 27.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit (ANCC)

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 27.5 contact hours of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 27.5 contact hours.

AANP (American Association of Nurse Practitioners) Credit

This program is approved for 27.5 contact hour(s) of continuing education (which includes 22.0 hours of pharmacology) by the American Association of Nurse Practitioners. Program ID 1408362. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

Registered Dietitian Credit

Medical Education Resources is an accredited CPE provider for the Commission on Dietetic Registration.

Pharmacy Credit



Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 27.5 contact hours (2.75 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Program Number – 0816-9999-14-002-L01-P) This activity is certified as Knowledge based CPE.

DISCLOSURE OF CONFLICTS OF INTEREST

It is the policy of Medical Education Resources to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Content Managers

The following content managers reported no financial relationships with commercial interests whose products or services may be mentioned in this CME/CE activity:

Medical Education Resources: Julie Johnson, PharmD, Stephen Scharmann, MD, Veronda Smith, FNP

HealthScience Media, Inc: Mary Mihalovic, Nicola Sirdevan, Melissa Wiles

DISCLAIMER

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, HealthScience Media, Inc and/or the various industry supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. MER's ANCC accreditation status does not imply endorsement by MER or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

LEARNING OBJECTIVES

TARGET AUDIENCE & LEARNING OBJECTIVES

The CMHC is designed for advanced-level clinicians responsible for the prevention, diagnosis, and management of cardiometabolic risk. At the end of the congress, participants will be able to:

1. Explain the interrelationships among the various cardiometabolic risk factors, their impact on cardiovascular health, and their common comorbidities.
2. Translate evidence-based strategies for prevention, screening, and treatment of cardiometabolic risk factors and their comorbidities to their clinical practice.
3. Identify which interventions, including lifestyle changes and various drugs in combination, are most appropriate for particular patients based on their risk profiles.
4. Identify how novel and emerging therapies can be integrated into clinical practice to reduce morbidity and mortality from cardiovascular and metabolic disease.

PURPOSE STATEMENT

To improve patient outcomes through early identification and intervention strategies for patients with, or at risk of developing, diabetes and cardiovascular disease.

NEW THIS YEAR!

HOW TO CLAIM CME/CE CREDITS

In order to obtain your CME/CE credits for the 2014 Cardiometabolic Health Congress (CMHC), please complete both steps below:

- On-site: Please submit your completed CME symposia evaluation forms for each symposium that you attend in the evaluation drop box outside the symposium room or submit to staff at the CMHC registration desk.
- Post-conference: You will receive an email containing a link to complete your CMHC Program Evaluation. Online evaluations must be completed by **November 28, 2014**.

CME/CE Certificates will be available for print immediately upon completion of the online evaluation form.

Pharmacists Only: The record of your participation in this CE activity will be uploaded to the CPE Monitor under your NABP e-profile within 60 days. You may print an individual statement of credit for this activity from your NABP e-profile.

Online
CME/CE
Activities

ACCESS THE LATEST
Cardiometabolic Online Education
EARN ACCME, ANCC, or CDR Credit
www.cmhc-online.com

Thursday, October 23, 2014

6:15 – 7:45am	CME Breakfast Symposium A	Constitution Ballroom
6:15 – 7:45am	CME Breakfast Symposium B	Republic Ballroom
8:00 – 10:30am	General Session	Grand Ballroom
10:30 – 11:30am	Morning Break/Exhibit Hall	Hynes Convention Center
11:30am – 12:30pm	General Session	Grand Ballroom
12:45 – 2:15pm	CME Lunch Symposium A	Constitution Ballroom
12:45 – 2:15pm	CME Lunch Symposium B	Republic Ballroom
12:45 – 2:15pm	CME Lunch Symposium C	Back Bay Ballroom
2:30 – 3:30pm	General Session	Grand Ballroom
3:30 – 4:15pm	Afternoon Break/Exhibit Hall	Hynes Convention Center
4:45 – 5:45pm	General Session	Grand Ballroom
5:45 – 7:00pm	Welcome Reception	Hynes Convention Center
7:00 – 9:00pm	CME Dinner Symposium A	Republic Ballroom
7:00 – 9:00pm	CME Dinner Symposium B	Constitution Ballroom

Friday, October 24, 2014

6:15 – 7:45am	CME Breakfast Symposium A	Constitution Ballroom
6:15 – 7:45am	CME Breakfast Symposium B	Republic Ballroom
6:15 – 7:45am	CME Breakfast Symposium C	Back Bay Ballroom
8:00 – 10:10am	General Session	Grand Ballroom
10:10 – 11:15am	Morning Break/Exhibit Hall	Hynes Convention Center
11:15am – 12:15pm	General Session	Grand Ballroom
12:30 – 2:00pm	CME Lunch Symposium A	Republic Ballroom
12:30 – 2:00pm	CME Lunch Symposium B	Constitution Ballroom
12:30 – 2:00pm	CME Lunch Symposium C	Back Bay Ballroom
2:00 – 3:30pm	General Session	Grand Ballroom
3:30 – 4:15pm	Afternoon Break/Exhibit Hall	Hynes Convention Center
4:15 – 5:45pm	General Session	Grand Ballroom
6:00 – 7:00pm	Symposium A (non-CME)	Fairfax Ballroom
6:00 – 7:00pm	Symposium B (non-CME)	Commonwealth Ballroom
7:00 – 9:00pm	CME Dinner Symposium A	Constitution Ballroom
7:00 – 9:00pm	CME Dinner Symposium B	Republic Ballroom

Saturday, October 25, 2014

6:15 – 7:45am	CME Breakfast Symposium	Constitution Ballroom
8:00 – 10:00am	General Session	Grand Ballroom
10:00 – 10:15am	Morning Break	Grand Ballroom
10:15am – 12:30pm	General Session	Grand Ballroom

Thursday, October 23, 2014

- 6:15 – 7:45am**
Constitution Ballroom
- CME Breakfast Symposium A**
The Triglycerides Conundrum: Practical Clinical Guidance for Reducing Residual CV Risk
Harold E. Bays, MD (Chair); Christie M. Ballantyne, MD; Eliot A. Brinton, MD
Supported by an educational grant from Amarin Pharma, Inc.
- 6:15 – 7:45am**
Republic Ballroom
- CME Breakfast Symposium B**
Confronting Racial and Ethnic Disparities in Cardiometabolic Disease
Laurence Sperling, MD (Chair); Keith C. Ferdinand, MD; JoAnne M. Foody, MD; Kris Vijay, MD
Sponsored by the American College of Cardiology in collaboration with the National Minority Quality Forum and the Association of Black Cardiologists | Supported in part by educational grants from Arbor Pharmaceuticals and Merck & Co.
- SESSION I: DYSLIPIDEMIA, ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE RISK REDUCTION**
- 8:00 – 8:10am**
Grand Ballroom
- Opening Remarks**
Christie M. Ballantyne, MD
- 8:10 – 9:40am**
Grand Ballroom
- CVD Prevention Guidelines Update: Clinical Impact and Current Controversies**
moderator: *Christie M. Ballantyne, MD*
presenters & discussants: *George L. Bakris, MD; Robert H. Eckel, MD; Jay S. Skyler, MD; Sidney C. Smith, Jr., MD; Neil J. Stone, MD*
- 9:40 – 10:30am**
- KEYNOTE SESSION**
Update on Inflammation in the Pathogenesis of Cardiometabolic Disease
Peter Libby, MD
Testing the Inflammation Hypothesis: The CIRT and CANTOS Trials
Paul M. Ridker, MD
- 10:30 – 11:30am**
- Morning Break/Exhibit Hall • Hynes Convention Center**
Meet the Experts Session • Booth #321 • 10:45 - 11:05am
- 11:30 – 12:30pm**
Grand Ballroom
- Late-Breaking Clinical Trials and FDA Update**
moderator: *Christie M. Ballantyne, MD*
presenters & discussants: *Deepak L. Bhatt, MD, MPH; Robert H. Eckel, MD; Keith C. Ferdinand, MD; Jay S. Skyler, MD*
- 12:45 – 2:15pm**
Constitution Ballroom
- CME Lunch Symposium A**
Obesity Management 2014: New Perspectives and Therapeutic Options for a Growing Problem
Robert H. Eckel, MD (Chair); Jamy D. Ard, MD; George A. Bray, MD; Michael D. Jensen, MD
Supported by an educational grant from Novo Nordisk, Inc.
- 12:45 – 2:15pm**
Republic Ballroom
- CME Lunch Symposium B**
Closing the Gaps in the Continuum of Care for Patients with Acute Coronary Syndromes: Implications for Optimal Antiplatelet Use
Deepak L. Bhatt, MD, MPH (Chair); Jeffrey L. Anderson, MD; Robert A. Harrington, MD; P. Gabriel Steg, MD
Supported by an educational grant from AstraZeneca
- 12:45 – 2:15pm**
Back Bay Ballroom
- CME Lunch Symposium C**
Evolving Strategies for LDL-Lowering: Novel Targets and Treatments for CVD Risk Reduction
Terry A. Jacobson, MD (Chair); Eliot A. Brinton, MD; Sekar Kathiresan, MD; Evan A. Stein, MD, PhD
Supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals

Thursday, October 23, 2014 (continued)

2:30 – 3:30pm
Grand Ballroom

Expert Debates in Antithrombotic Therapy
moderator: *Deepak L. Bhatt, MD, MPH*
presenters & discussants: *Robert A. Harrington, MD; P. Gabriel Steg, MD*

3:30 – 4:15pm

Afternoon Break/Exhibit Hall • Hynes Convention Center
Meet the Experts Session • Booth #321 • 3:45 - 4:05pm

4:15 – 4:45pm
Grand Ballroom

KEYNOTE SESSION
Implications of Recent Genetic Findings on Management of Cardiovascular Risk
Sekar Kathiresan, MD

4:45 – 5:45pm
Grand Ballroom

Clinical Controversies in Lipid Management: Case-Based Presentations & Discussion
moderator: *Christie M. Ballantyne, MD*
presenters & discussants: *Robert H. Eckel, MD; JoAnne M. Foody, MD; Sekar Kathiresan, MD; Neil J. Stone, MD*

5:45pm
Grand Ballroom

Closing Remarks
Christie M. Ballantyne, MD

5:45 – 7:00pm

Exhibit Hall Welcome Reception • Hynes Convention Center
Meet the Experts Session • Booth #321 • 6:00 - 6:20pm

7:00 – 9:00pm
Republic Ballroom

CME Dinner Symposium A
The Wide Spectrum of Familial Hypercholesterolemia: Discovering Your Highest Risk Patients and Optimizing Treatment
Seth J. Baum, MD (Chair); Catherine Davis Ahmed; Sarah de Ferranti, MD, MPH; Patrick M. Moriarty, MD; Pamela B. Morris, MD; Scott Radabaugh
Supported by educational grants from Aegerion Pharmaceuticals, Inc. and Genzyme, A SANOFI COMPANY | Endorsed by The FH Foundation

7:00 – 9:00pm
Constitution Ballroom

CME Dinner Symposium B
Novel and Emerging Combinations to Achieve Glycemic Control and Reduce Cardiometabolic Risk: A Focus on Incretin-Based Therapy and SGLT2 Inhibitors
George L. Bakris, MD (Chair); Mark E. Molitch, MD;

Join us in the
CMHC EXHIBIT HALL for our
WELCOME RECEPTION

Thursday, October 23 • 5:45 - 7:00pm
Hynes Convention Center



Friday, October 24, 2014

- 6:15 – 7:45am**
Constitution Ballroom
- CME Breakfast Symposium A**
Optimizing Antihypertensive Therapies in High-Risk and Difficult-to-Treat Patients with Hypertension
George L. Bakris, MD (Chair); Keith C. Ferdinand, MD; Thomas Giles, MD; Michael A. Weber, MD
Supported by an educational grant from Forest Laboratories, Inc.
- 6:15 – 7:45am**
Republic Ballroom
- CME Breakfast Symposium B**
Innovations in GLP-1 Receptor Agonist Therapy: Individualized Treatment Strategies to Overcome Barriers and Reduce Cardiometabolic Risk in Type 2 Diabetes Mellitus
John B. Buse, MD, PhD (Chair); Samuel Dagogo-Jack, MD; Richard E. Pratley, MD
Supported by an educational grant from Lilly USA, LLC
- 6:15 – 7:45am**
Back Bay Ballroom
- CME Breakfast Symposium C**
New Targets and Treatments for LDL Lowering: Role of PCSK9 Inhibitors
Christie M. Ballantyne, MD (Chair); Michael H. Davidson, MD; Marc S. Sabatine, MD, MPH; James A. Underberg, MD
Supported by an educational grant from Amgen

SESSION II: HYPERTENSION AND CARDIO-RENAL SYNDROME

- 8:00 – 8:10am**
Grand Ballroom
- Opening Remarks**
George L. Bakris, MD
- 8:10 – 8:40am**
Grand Ballroom
- Low Diastolic BP and Progression to CKD**
Aldo J. Peixoto, MD
- 8:40 – 9:10am**
Grand Ballroom
- Device Therapy & Resistant Hypertension**
George L. Bakris, MD
- 9:10 – 9:40am**
Grand Ballroom
- New Methodologies for the Management of Hyperkalemia in Kidney Disease**
Matthew R. Weir, MD
- 9:40 – 10:10am**
Grand Ballroom
- The Contribution of Aldosterone in Obesity-Related Hypertension**
Colleen M. Majewski, MD
- 10:10 – 11:15am**
- Morning Break/Exhibit Hall • Hynes Convention Center**
Meet the Experts Session • Booth #321 • 10:25 - 10:45am
- 11:15am – 12:15pm**
Grand Ballroom
- Clinical Controversies in Hypertension Management**
moderator: *George L. Bakris, MD*
presenters & discussants: *Colleen M. Majewski, MD; Aldo J. Peixoto, MD; Matthew R. Weir, MD*

Friday, October 24, 2014 (continued)

12:30 – 2:00pm
Republic Ballroom

CME Lunch Symposium A
**Triglyceride and Mixed Dyslipidemia Management:
The Changing Landscape of CV Risk Reduction**
*Christie M. Ballantyne, MD (Chair); Terry A. Jacobson, MD;
Michael Miller, MD; Dariush Mozaffarian, MD, DrPH*
Supported by an educational grant from AstraZeneca

12:30 – 2:00pm
Constitution Ballroom

CME Lunch Symposium B
**New Frontiers in Obesity Management:
Advances in Neurobiological Treatment Strategies**
*Caroline M. Apovian, MD (Chair); Louis J. Aronne, MD; Lee M. Kaplan, MD, PhD;
Joshua Thaler, MD, PhD*
Supported by an educational grant from Takeda Pharmaceuticals International, Inc., US Region
and Orexigen

12:30 – 2:00pm
Back Bay Ballroom

CME Lunch Symposium C
**Individualizing Therapy in Patients with Stable Ischemic Heart Disease:
Managing the Full Spectrum of Comorbidities and Cardiometabolic Risk Factors**
*JoAnne M. Foody, MD (Chair); Suzanne V. Arnold, MD; Deepak L. Bhatt, MD, MPH;
Peter H. Stone, MD*
Supported by an educational grant from Gilead Sciences, Inc.

SESSION III: DIABETES MANAGEMENT

2:00 – 2:30pm
Grand Ballroom

Is Alzheimer's Disease Type 3 Diabetes?
C. Ronald Kahn, MD

2:30 – 3:00pm
Grand Ballroom

Type 2 Diabetes Management 2014
John B. Buse, MD, PhD

3:00 – 3:30pm
Grand Ballroom

Initiating and Monitoring Insulin Therapy
Howard A. Wolpert, MD

3:30 – 4:15pm

Afternoon Break/Exhibit Hall • Hynes Convention Center
Meet the Experts Session • Booth #321 • 3:45 - 4:05pm

4:15 – 4:45pm
Grand Ballroom

The Bionic Pancreas
Edward R. Damiano, PhD

4:45 – 5:45pm
Grand Ballroom

Diabetes Panel Session
moderator: *Jay S. Skyler, MD*
discussants: *John B. Buse, MD, PhD; Edward R. Damiano, PhD;
C. Ronald Kahn, MD; Howard A. Wolpert, MD*

5:45pm

Closing Remarks
Jay S. Skyler, MD

6:00 – 7:00pm
Fairfax Ballroom

Symposium A (non-CME)
Take a Closer Look at Homozygous Familial Hypercholesterolemia
Daniel Wise, MD
Sponsored by Aegerion Pharmaceuticals

6:00 – 7:00pm
Commonwealth Ballroom

Symposium B (non-CME)
Treatment Considerations for Generalized Lipodystrophy
Jean Chan, MD
Sponsored by AstraZeneca

Friday, October 24, 2014 (continued)

- | | |
|---|---|
| <p>7:00 – 9:00pm
Constitution Ballroom</p> | <p>CME Dinner Symposium A
 Improving Awareness and Outcomes in Lipodystrophy Syndromes: Clinical Manifestations, Diagnosis, and Evolving Therapeutic Strategies
 <i>Abhimanyu Garg, MD (Chair); Rebecca J. Brown, MD; Elif A. Oral, MD; Andra Stratton</i>
 Supported by an educational grant from AstraZeneca Endorsed by Lipodystrophy United</p> |
| <p>7:00 – 9:00pm
Republic Ballroom</p> | <p>CME Dinner Symposium B
 Integrated Management of the Complexities of Cardiometabolic Diseases: A Patient-Centric Team Approach
 <i>Lawrence Blonde, MD (Chair); Honey E. East, MD; Martha M. Funnell, MS, RN, CDE; Daniel M. Riche, PharmD, BCPS, CDE</i>
 Supported by an educational grant from Merck & Co., Inc.</p> |

Saturday, October 25, 2014

- | | |
|---|---|
| <p>6:15 – 7:45am
Constitution Ballroom</p> | <p>CME Breakfast Symposium
 Overcoming Obstacles in Obesity Management: New Tools, Techniques, and Treatment Strategies
 <i>Louis J. Aronne, MD (Chair); Caroline M. Apovian, MD; Harold E. Bays, MD; Thomas A. Wadden, PhD</i>
 Supported by an educational grant from Eisai, Inc.</p> |
|---|---|

SESSION IV: LIFESTYLE AND OBESITY MANAGEMENT

- | | |
|--|---|
| <p>8:00 – 8:10am
Grand Ballroom</p> | <p>Opening Remarks
<i>Robert H. Eckel, MD</i></p> |
| <p>8:10 – 8:50am
Grand Ballroom</p> | <p>Impact of Gut Microbiota on Obesity and CVD Risk
<i>Peter J. Turnbaugh, PhD</i></p> |
| <p>8:50 – 9:30am
Grand Ballroom</p> | <p>Long-Term Effects of Metabolic Surgery
<i>Lee M. Kaplan, MD, PhD; Francesco Rubino, MD</i></p> |
| <p>9:30 – 10:00am
Grand Ballroom</p> | <p>Sleep Apnea and Restricted Sleep Patterns: Impact on Cardiometabolic Health
<i>Virend K. Somers, MD, PhD</i></p> |
| <p>10:00 – 10:15am</p> | <p>Morning Break</p> |
| <p>10:15 – 11:00am
Grand Ballroom</p> | <p>Long-Term Use of Obesity Medications: How to Sustain Weight Loss
<i>Caroline M. Apovian, MD</i></p> |
| <p>11:00 – 11:30am
Grand Ballroom</p> | <p>Behavioral Strategies in Obesity Management
<i>Thomas A. Wadden, PhD</i></p> |
| <p>11:30 – 11:50am
Grand Ballroom</p> | <p>Role of Exercise in the Modulation of Nontraditional CHD Risk Factors
<i>William E. Kraus, MD</i></p> |
| <p>11:50 – 12:30pm
Grand Ballroom</p> | <p>Obesity Panel Discussion
 moderator: <i>Robert H. Eckel, MD</i>
 discussants: <i>Caroline M. Apovian, MD; Lee M. Kaplan, MD, PhD; William E. Kraus, MD; Francesco Rubino, MD; Virend K. Somers, MD, PhD; Peter J. Turnbaugh, PhD; Thomas A. Wadden, PhD</i></p> |
| <p>12:30pm
Grand Ballroom</p> | <p>Closing Remarks
<i>Robert H. Eckel, MD</i></p> |



George L. Bakris, MD

Professor of Medicine
Director, ASH Comprehensive Hypertension Center
University of Chicago Medicine
Pritzker School of Medicine

Dr. Bakris received his medical degree from the Chicago Medical School and completed residency in Internal Medicine at the Mayo Graduate School of Medicine where he also did a research fellowship in Physiology and Biophysics. He then completed fellowships in Nephrology and Clinical Pharmacology at the University of Chicago. From 1988 to 1991 he served as Director of Renal Research at the Ochsner Clinic and was a faculty member of Tulane University School of Medicine. He was also Professor and Vice Chairman of Preventive Medicine and Director of the Rush University Hypertension Center in Chicago, IL (USA) from 1993 until 2006. Currently, he is Professor of Medicine and Director, Hypertensive Diseases Unit in the Section of Endocrinology, Diabetes and Metabolism at the University of Chicago Pritzker School of Medicine.

Dr. Bakris has published over 400 articles and book chapters in the areas of kidney disease hypertension and progression of nephropathy. He is the Editor or Co-Editor of eight books, all dealing with Kidney Disease, Diabetes and the role of Hypertension and include: The Kidney and Hypertension, Hypertension: a Clinician's Guide to Diagnosis and Treatment and Hypertension: Principles and Practice, Handbook of Hypertension, The Kidney in Cardiovascular Disease, Therapeutic Strategies in Hypertension, Microalbuminuria and Cardiovascular Risk and Lower Extremity Arterial Disease. Additionally, he is the Associate Editor of the International Textbook of Cardiology. He has also served as the co-principal investigator of an NIH Clinical Research training grant (K30) to train clinical researchers (1999-2004). He chaired the National Kidney Foundation Consensus report on blood pressure and impact on renal disease progression (2000). He has also served on many national committees including: the JNC 7 executive and writing committee (2003), the American Diabetes Association Clinical Practice Guideline Committee (2003-2004), the National Kidney Foundation (K-DOQI) Blood Pressure Guideline committee (2002-2004), the National Kidney Foundation (K-DOQI) Diabetes Guideline committee (2003-2005), the JNC VI writing committee (1997), and the NIH National High Blood Pressure Education Program Working Group on Hypertension and Renal Disease (1994). He also serves as an expert-consultant to the Cardio-renal Advisory Board of the FDA (1993-present). Dr. Bakris is also the past- president of the American College of Clinical Pharmacology (2000-2002). He is the current Editor of Am J Nephrology and the Hypertension Section Editor of Up-to-Date. He serves on more than 12 editorial boards including Diabetes Care, Kidney International, Nephrology, Dialysis & Transpl. Hypertension, J Clin Hypertension and J of Hypertension.

Grants/Research Support: None

Consulting Fees: AbbVie, Bayer, Janssen, Boehringer Ingelheim, Daiichi-Sankyo Inc, Novartis, AstraZeneca, Orexigen

Speakers' Bureau: None



Christie M. Ballantyne, MD

Professor of Medicine
Chief, Section of Cardiovascular Research
Chief, Section of Cardiology
Department of Medicine, Baylor College of Medicine
Director, Center for Cardiovascular Disease Prevention
Baylor College of Medicine
Methodist DeBakey Heart Center

Christie M. Ballantyne, M.D., is Director of the Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center; Chief of the Section of Cardiovascular Research, Donald P. Chapman Endowed Chair of Cardiology, Chief of the Section of Cardiology, Department of Medicine, Baylor College of Medicine; Director of the Maria and Alando J. Ballantyne, M.D., Atherosclerosis Laboratory; Professor of Medicine, Professor of Genetics, Professor of Physiology with a joint appointment in Pediatrics, Baylor College of Medicine; and Co-Director, Lipid Metabolism and Atherosclerosis Clinic, The Methodist Hospital, Houston, Texas. He received his Doctor of Medicine from Baylor College of Medicine, and his postgraduate training included an internal medicine residency at The University of Texas Southwestern Medical School, Dallas, Texas, a cardiology fellowship at Baylor College of Medicine, and an American Heart Association/Bugher Foundation Fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor. Dr. Ballantyne is a Fellow of the American Association for the Advancement of Science, member of the American Society for Clinical Investigation, Fellow of the American College of Cardiology, and Fellow of the American College of Physicians. He previously served as governor of the Texas Chapter of the American College of Cardiology and president of the Houston Chapter of the American Heart Association. Dr. Ballantyne has been the recipient of numerous study grants, including an American Heart Association Established Investigator Award and several NIH grants to study leukocyte-endothelial adhesion molecules and novel biomarkers for atherosclerosis. He has been a member of numerous steering committees for multicenter trials, including the Atherosclerosis Risk in Communities (ARIC) study, Improved Reduction of Outcomes: Vitorin Efficacy International Trial (IMPROVE IT), A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID), DAL Outcomes, and has also participated as a member of several Data and Safety Monitoring Boards. Dr. Ballantyne is Editorial Director for www.lipidsonline.org. He has published extensively and has spoken nationally and internationally on lipids, atherosclerosis, and inflammation. Dr. Ballantyne's research interests include the pathophysiology of atherosclerosis, with an emphasis on monocyte activation and adhesion. His clinical interests include preventive cardiology, lipids, metabolic syndrome, atherosclerosis, genetics, and coronary artery disease.

Grants/Research Support: Abbott Diagnostics, Amarin, Amgen, Eli Lilly, Esperion, GlaxoSmithKline, Genentech, Merck, Novartis, Pfizer, Regeneron, Roche, Roche Diagnostic, Sanofi-Synthelabo, National Institutes of Health, American Heart Association

Consulting Fees: Abbott Diagnostics, Aegerion, Amarin, Amgen, Arena, Cerenis, Esperion, Genentech, Genzyme, Kowa, Merck, Novartis, Pfizer, Resverlogix, Regeneron, Roche, Sanofi-Synthelabo

Speakers' Bureau: None

CHAIRPERSONS

**Robert H. Eckel, MD**

Professor of Medicine
 Division of Endocrinology, Metabolism and Diabetes
 Division of Cardiology
 Professor of Physiology and Biophysics
 Charles A. Boettcher II Chair in Atherosclerosis
 Director, Discovery Translation
 Colorado Clinical & Translational Science Institute
 University of Colorado Anschutz Medical Campus
 Director, Lipid Clinic, University Hospital

Dr. Eckel is the Charles A Boettcher II Endowed Chair in Atherosclerosis, Professor of Medicine with appointments in the Division of Endocrinology, Metabolism and Diabetes and the Division of Cardiology, and Professor of Physiology and Biophysics at the University of Colorado School of Medicine Anschutz Medical Campus, and Director of the Lipid Clinic at the University of Colorado Hospital. He is also the Program Director of the National Center for Research Resources (NCRR) Discovery Translation component of the Colorado Clinical Translational Sciences Institute, and previously served as Program Director of the Adult General Clinical Research Center at UCD for 15 years. In addition, Dr. Eckel previously was a member of the Scientific Advisory Council of the National Institute of Diabetes, Digestive and Kidney Diseases at the National Institutes of Health (NIH) and Past President of the American Heart Association. His NIH funded research has focused on the pathogenesis and treatment of lipid disorders, obesity, the metabolic syndrome, diabetes, and obstructive sleep apnea. Studies in animals and humans are directed towards dissecting the impact of nutrition/hormones on lipid and carbohydrate fuel partitioning and energy balance.

In humans, Dr. Eckel has examined the nutritional/metabolic predictors of weight change, lipid disorders, inflammation, and atherosclerosis. In the laboratory, he uses genetically modified mice with tissue-specific overexpression or deletion of lipid-related gene expression and tissue culture to address similar issues in more extensive and mechanistic detail. Overall, Dr. Eckel's research is targeted to uncovering basic mechanisms of how metabolic diseases relate to cardiovascular and pulmonary disease in hopes that the data to be gathered will lead to more favorable diagnostics and therapeutics to follow.

Grants/Research Support: Esperion, Novo Nordisk

Consulting Fees: FoodMinds LLC, Pfizer, Abbott, Merck, Novo Nordisk

Speakers' Bureau: None

**Jay S. Skyler, MD, MACP**

Professor of Medicine, Pediatrics, & Psychology
 Division of Endocrinology, Diabetes & Metabolism
 University of Miami Miller School of Medicine
 Deputy Director for Clinical & Academic Programs
 Diabetes Research Institute

Jay S. Skyler, MD, MACP, is currently a Professor of Medicine, Pediatrics, & Psychology, in the Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida. He served as Director of that Division from 2000 to 2004. At the University of Miami, he is Associate Director for Academic Programs in the Diabetes Research Institute. He is Chairman of the NIH (NIDDK)-sponsored Type 1 Diabetes TrialNet, an international network conducting clinical trials to prevent type 1 diabetes or interdict the type 1 diabetes disease process. His research interests are in clinical aspects of diabetes, particularly improving the care of type 1 diabetes through meticulous glycemic control, psychosocial and behavioral support, and immune intervention. He is widely acclaimed for developing "algorithms" for patient adjustment of insulin doses. He is a past President of the American Diabetes Association, the International Diabetes Immunotherapy Group, and the Southern Society for Clinical Investigation, and was a Vice-President of the International Diabetes Federation. He served as a member of the Endocrinology, Diabetes, and Metabolism Subspecialty Examining Board of the American Board of Internal Medicine, as Chairman of the Council of Subspecialty Societies of the American College of Physicians (ACP) and a member of the ACP Board of Regents. He was founding Editor-in-Chief of *Diabetes Care*, and currently is Scientific Editor of *International Diabetes Monitor* and Associate Editor of *Diabetes Technology & Therapeutics*.

Grants/Research Support: Mesoblast, Viacyte

Consulting Fees: AstraZeneca/Bristol-Myers Squibb, Elcelyx, Ideal Life, Novo Nordisk, NPS Pharma, PhaseBio, Boehringer Ingelheim, Halozyme, Intarcia, Orgenesis, Sanofi, Valeritas, Viacyte, Dance Biopharm, DexCom Corporation, SynAlpha

Speakers' Bureau: None

Ownership Interest/Shareholder: Dance Biopharm, DexCom Corporation, Ideal Life, SynAlpha, Tandem Diabetes Care



Caroline M. Apovian, MD

Professor of Medicine
Boston University School of Medicine
Director, Center for Nutrition and Weight Management
Boston Medical Center

Dr. Caroline M. Apovian is Professor of Medicine and Pediatrics, in the Section of Endocrinology, Diabetes, and Nutrition at Boston University School of Medicine, USA. She is also Director of the Center for Nutrition and Weight Management at Boston Medical Center, USA. Dr Apovian is a nationally and internationally recognized authority on nutrition and has been in the field of obesity and nutrition since 1990. Her current research interests are in: weight loss and its effects on endothelial cell function, adipose cell metabolism and inflammation, research in the bariatric surgery population, and novel pharmacotherapeutic antiobesity agents. She has become an expert in the technique for subcutaneous adipose tissue biopsies, and has been performing these biopsies on research subjects for over 5 years.

Dr Apovian was a recipient of the Physician Nutrition Specialist Award given by the American Society of Clinical Nutrition. This was for her work on developing and providing nutrition education, to medical students and physicians in training at Boston University School of Medicine. She has published over 100 articles, chapters, and reviews on the topics of: obesity, nutrition, and the relationship between adipose tissue and risk of developing cardiovascular disease. Dr. Apovian has recently published a new book entitled the "Overnight Diet" and has also written a popular book for patients called "The ALLI Diet Plan".

Dr Apovian has been a member of The Obesity Society since 1992, and has served on the Clinical Committee as well as Secretary/Treasurer and the Executive Committee from 2005 to 2008. She is currently planning next year's Annual Meeting as Chair of the Clinical Track. She has been a faculty speaker and has presented papers at several of the Society's Annual Scientific Meeting. Additionally, she serves as Associate Editor for the Society's journal, Obesity.

Grants/Research Support: Lilly, Amylin, Aspire Bariatrics, GI Dynamics, Pfizer, Sanofi-Aventis, Orexigen, MetaProteomics, Robert and Veronica Atkins Foundation

Consulting Fees: Amylin, Merck, Johnson & Johnson, Arena, Nutrisystem, Zafgen, Sanofi-Aventis, Orexigen, EnteroMedics

Speakers' Bureau: None



Deepak L. Bhatt, MD, MPH

Professor of Medicine
Harvard Medical School
Executive Director
Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart and Vascular Center

Deepak L. Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC, is Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center and Professor of Medicine at Harvard Medical School. He is also a Senior Physician at Brigham and Women's Hospital and a Senior Investigator in the TIMI Study Group.

After graduating as valedictorian from the Boston Latin School, Dr. Bhatt obtained his undergraduate science degree as a National Merit Scholar at the Massachusetts Institute of Technology while also serving as a research associate at Harvard Medical School. He received his medical doctorate from Cornell University. He completed a Masters in Public Health with a concentration in clinical effectiveness at Harvard University. His internship and residency in internal medicine were performed at the Hospital of the University of Pennsylvania, and his cardiovascular training was completed at Cleveland Clinic. He also completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention as well as serving as Chief Interventional Fellow at Cleveland Clinic where he spent several years as an interventional cardiologist and an Associate Professor of Medicine. He served for many years as Director of the Interventional Cardiology Fellowship and as Associate Director of the Cardiovascular Medicine Fellowship. He also served as Associate Director of the Cleveland Clinic Cardiovascular Coordinating Center. He was then recruited to be the Chief of Cardiology at VA Boston Healthcare System where he served for several years. Dr. Bhatt was listed in Best Doctors in America from 2005 to 2014.

Dr. Bhatt's research interests include preventive cardiology as well as the optimal management of patients with acute coronary syndromes. He also has research interests in advanced techniques in cardiac, cerebral, and peripheral intervention. He has authored or co-authored over 600 publications. He is on several editorial boards. He is the editor of Essential Concepts in Cardiovascular Intervention and Guide to Peripheral and Cerebrovascular Intervention. He was the international PI for the CHARISMA and CRESCENDO trials and co-PI of the three CHAMPION trials. He served as chair of COGENT and helped lead STAMPEDE. He serves as co-chair of the REACH registry. He is also co-PI of SAVOR-TIMI 53 and SYMPLICITY HTN-3 and chairs REDUCE-IT. He is the current Chair of the AHA-GWTG Steering Committee. He is Associate Editor for clinical trials for the ACC's Cardiosource. Dr. Bhatt has been a visiting lecturer at a number of prestigious institutions throughout the world. He has been interviewed extensively by news agencies on topics ranging from premature coronary artery disease to the role of genetics in heart attacks. He is the Editor-in-Chief of the Harvard Heart Letter.

Grants/Research Support: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi Aventis, The Medicines Company

Consulting Fees: None

Speakers' Bureau: None

DISTINGUISHED FACULTY

**John Buse, MD, PhD**

Verne S. Caviness Distinguished Professor
Chief, Division of Endocrinology
Director, Diabetes Care Center
Executive Associate Dean for Clinical Research
University of North Carolina School of Medicine

Dr. Buse received his MD and PhD from Duke University before training in internal medicine and endocrinology at the University of Chicago. He is currently a professor at the University of North Carolina School of Medicine where he serves as the Chief of the Division of Endocrinology, Director of the Diabetes Care Center and Executive Associate Dean for Clinical Research.

Dr. Buse conducts multicenter and single site clinical trials in the prevention and treatment of type 1 diabetes, type 2 diabetes and diabetes complications. He has authored more than 200 publications. He serves on the Steering Committee or Data Safety Monitoring Board for NIH and international studies such as ACCORD, IRIS, FREEDOM, ORIGIN, ALECARDIO, TECOS, LEADER, EXSCEL and GRADE. He is heavily engaged in the North Carolina Translational and Clinical Science Institute, the UNC home of the NIH's Clinical and Translational Science Award (CTSA).

Dr Buse completed service as President for Medicine and Science at the American Diabetes Association in 2008. He has received numerous awards and honors, including the 2010 Castle Connolly National Physician of the Year award. He now serves as the Chair of the National Diabetes Education Program, a partnership of the National Institutes of Health, the Centers for Disease Control and Prevention, and more than 200 public and private organizations.

Grants/Research Support: Amylin, Andromeda, Astellas, AstraZeneca, Bayhill Therapeutics, Boehringer Ingelheim, GmbH & Co., KG, Bristol-Myers Squibb, Catabasis, Cebix, CureDM, Diartis Pharmaceuticals, Elcelyx Therapeutics, Eli Lilly, Exculin, Genentech, GI Dynamics, GlaxoSmithKline, Halozyme Therapeutics, F. Hoffman-LaRoche, Intarcia Therapeutics, Johnson & Johnson, Lexicon, LipoScience, Macrogenics, Medtronic, Merck, Metabolic Solutions Development, Metabolon, Metavention, Novan, Novo Nordisk A/S, Orexigen Therapeutics, Osiris Therapeutics, Pfizer, PhaseBio Pharmaceuticals, Quest Diagnostics, Rhythm Pharmaceuticals, Sanofi, Spherix, Takeda, ToleRx, Transpharma Medical, TransTech Pharma, Veritas, Verva

Consulting Fees: Amylin, Andromeda, Astellas, AstraZeneca, Bayhill Therapeutics, Boehringer Ingelheim, GmbH & Co., KG, Bristol-Myers Squibb, Catabasis, Cebix, CureDM, Diartis Pharmaceuticals, Elcelyx Therapeutics, Eli Lilly, Exculin, Genentech, GI Dynamics, GlaxoSmithKline, Halozyme Therapeutics, F. Hoffman-LaRoche, Intarcia Therapeutics, Johnson & Johnson, Lexicon, LipoScience, Macrogenics, Medtronic, Merck, Metabolic Solutions Development, Metabolon, Metavention, Novan, Novo Nordisk A/S, Orexigen Therapeutics, Osiris Therapeutics, Pfizer, PhaseBio Pharmaceuticals, Quest Diagnostics, Rhythm Pharmaceuticals, Sanofi, Spherix, Takeda, ToleRx, Transpharma Medical, TransTech Pharma, Veritas, Verva

Speakers' Bureau: None

**Edward R. Damiano, PhD**

Associate Professor of Biomedical Engineering
Boston University

Edward Damiano is an Associate Professor of Biomedical Engineering at Boston University. His expertise and training are in the areas of mechanical and biomedical engineering, applied mechanics, and applied mathematics. Ever since his 14-year-old son was diagnosed with type 1 diabetes at 11 months of age, he has been committed to creating and integrating closed-loop control technologies with a vision of building a bionic endocrine pancreas by the time his son heads off to college in the fall of 2017. This endeavor began with the design and development of mathematical algorithm strategies for blood glucose control, which he and his group began testing in his laboratory at Boston University in 2005 in a swine model of type 1 diabetes. In 2006, he began working with his clinical collaborators at the Massachusetts General Hospital (MGH) to design their first clinical protocol. Between 2008 and 2012, they tested their system in the inpatient setting in one-day and two-day experiments in adults and adolescents with type 1 diabetes in the Clinical Research Center at the MGH. Near the end of 2012 they received approval from the FDA to begin testing a mobile version of their system, which integrates an iPhone with their blood-glucose control algorithm, an insulin pump, and a continuous glucose monitor. Between February and September 2013, they conducted an ambitious outpatient trial testing their bi-hormonal bionic pancreas in five-day experiments in 20 adult subjects with type 1 diabetes in downtown Boston. In July and August 2013, they conducted their even more ambitious Summer Camp Study testing their bi-hormonal bionic pancreas in five-day experiments in 32 adolescent subjects with type 1 diabetes at Camp Joslin and the Clara Barton Camp in central Massachusetts.

Grants/Research Support: None

Consulting Fees: None

Speakers' Bureau: None



Keith C. Ferdinand, MD
Professor of Clinical Medicine
Tulane University School of Medicine
Chair, National Forum For Heart
Disease and Stroke Prevention

Dr. Ferdinand was a member of the ALLHAT Data Safety and Monitoring Board and chair of Section Four of the Sixth Report of the Joint National Committee. He was a member of the Ad Hoc Committee on Minority Populations for the National Heart Lung and Blood Institute (NHLBI), and a member of the National High Blood Pressure Education Program Coordinating Committee. He was director of the NHLBI Physician's Health Network, a program that educated physicians and the lay population on cardiovascular risk reduction.

He is past president and former member of the Louisiana State Board of Medical Examiners, past president of the Orleans Division of the American Heart Association, and past chair of the Board of Association of Black Cardiologists, Inc.

Dr. Ferdinand received his medical degree from Howard University College of Medicine. He is board certified in internal medicine and cardiovascular disease, a diplomat certified in the subspecialty of nuclear cardiology, an American Society of Hypertension certified specialist in clinical hypertension, and a Fellow of the American College of Cardiology, American Heart Association, the National Lipid Association and the American Society of Hypertension. Dr. Ferdinand has written for *Cardiology Clinics*, *Annual of Drug Therapy*, and *Cardiovascular Diseases in Blacks*. Dr. Ferdinand is Editor-in-Chief of the 2009 Educational Review Manual in Cardiovascular Disease (Castle Connolly). He is co-author of *Overcoming Katrina African American Voices from the Crescent City and Beyond* (Palgrave MacMillan 2009), a collection of 27 oral histories. He also is co-editor of *Cardiovascular Disease in Racial & Ethnic Minorities* (Humana Press 2009).

In 2004, Dr. Ferdinand received the Louis B. Russell, Jr. Memorial Award of the American Heart Association and the Walter M. Booker Community Service Award of the Association of Black Cardiologists. In 2010 he was recognized by the Congressional Black Caucus Health Trust with an award for journalism and the Charles Drew award for medical excellence in conjunction with the National Minority Quality Foundation.

Grants/Research Support: Eli Lilly, Boehringer Ingelheim

Consulting Fees: Amgen, Sanofi, Boehringer Ingelheim

Speakers' Bureau: None



JoAnne M. Foody, MD
Medical Director
Cardiovascular Wellness Program
Brigham and Women's Hospital
Associate Professor
Harvard Medical School

JoAnne M. Foody, MD, is Director of the Cardiovascular Wellness Center at Brigham and Women's Hospital and an Associate Professor of Medicine at Harvard Medical School, both in Boston. Dr. Foody has an active role in inpatient care, education and research. Her work is focused on improving cardiovascular outcomes through strengthening cardiac disease prevention and rehabilitation. Her research has focused on identifying and fostering greater use of clinical strategies that prevent adverse cardiovascular events in people with and without coronary artery disease. Dr. Foody also has had leadership roles on the National AMI and National Heart Failure projects of the Centers for Medicare & Medicaid Services. She is currently Editor of Braunwald's Preventive Cardiology text as well as serves as Editor of the American College of Cardiology's patient website, CardioSmart.org.

Grants/Research Support: None

Consulting Fees: Merck, Pfizer, Sanofi, Amarin, Boehringer Ingelheim, Janssen

Speakers' Bureau: None

DISTINGUISHED FACULTY

**Robert A. Harrington, MD**

Arthur L. Bloomfield Professor of Medicine
Chairman of the Department of Medicine
Stanford University

Dr. Robert Harrington is Arthur L. Bloomfield Professor of Medicine and Chairman of the Department of Medicine at Stanford University. Dr. Harrington was previously the director of the Duke Clinical Research Institute (DCRI) at Duke University. His research interests include evaluating antithrombotic therapies to treat acute ischemic heart disease and to minimize the acute complications of percutaneous coronary procedures, studying the mechanism of disease of the acute coronary syndromes, understanding the issue of risk stratification in the care of patients with acute ischemic coronary syndromes, trying to better understand and improve upon the methodology of clinical trials. His research has been funded through NIH, NIA, other peer reviewed agencies and private industry.

He has authored more than 400 peer-reviewed manuscripts, reviews, book chapters, and editorials. He is an associate editor of the American Heart Journal and an editorial board member for the JACC. He is a senior editor of the 13th edition of Hurst's The Heart and recently served as a member and the chair of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. He is currently a member of the American College of Cardiology Board of Trustees where he serves as Chair of the Life-Long Learning Oversight Committee. Harrington is a Fellow of the American College of Cardiology, the American Heart Association, the Society for Cardiac Angiography and Intervention, the European Society of Cardiology, the American College of Chest Physicians and the American College of Physicians. He is an elected member of the Association of American Physicians. Harrington serves as the Chair for the American Heart Association's Scientific Sessions in 2013 and 2014. Interested in innovative learning tools, including novel methods of communicating scientific information, Harrington hosts a regular podcast on theheart.org, The Bob Harrington Show and can be followed on Twitter at HeartBobH.

Grants/Research Support: The Medicines Company, Merck, AstraZeneca, Sanofi, Regado

Consulting Fees: TMC Pharma Services, Merck, Medtronic, Myokardia, Johnson & Johnson, Gilead, WebMD, ApoPharma

Speakers' Bureau: None

Ownership Interest/Shareholder: MyoKardia, Element Science, Adverse Events

**C. Ronald Kahn, MD**

Mary K. Iacocca Professor
Harvard Medical School
Chief Academic Officer
Joslin Diabetes Center

C. Ronald Kahn, M.D. received his undergraduate and medical degrees from the University of Louisville. After training in internal medicine at Washington University, he moved to the National Institutes of Health where he rose to become the Head of the Section on Cellular and Molecular Physiology of NIDDK. In 1981, he moved to Boston to become Research Director of the Joslin Diabetes Center. In 1984 he became Professor of Medicine at Harvard Medical School, and in 1986 the Mary K. Iacocca Professor. From 2000-2007, Kahn served as President and Director of the Joslin Diabetes Center. Under his leadership, Joslin research grew more than 20-fold, clinical and educational activity have tripled, and new programs were launched in a variety of areas, including new national business alliances.

Dr. Kahn is the preeminent investigator of insulin signal transduction and mechanisms of altered signaling in disease. His laboratory has produced multiple seminal observations regarding the insulin receptor kinase, its substrates, the molecular components of the insulin signaling network, and their alterations in disease that have revolutionized the field.

Dr. Kahn has received numerous honors and awards, including the highest scientific awards of the American Diabetes Association, Juvenile Diabetes Research Foundation, European Association for the Study of Diabetes, British Diabetes and British Endocrine Societies, International Diabetes Federation, American Federation of Clinical Research, and the Endocrine Society, as well as the Hamdan Award for Medical Research, the Rolf Luft Award of the Karolinska University, the Lawson Wilkins Award of the Pediatric Endocrine Society, the Beering Award of Indiana University, and the Allyn Taylor International Prize in Medicine. Dr. Kahn has served on many national commissions and advisory boards, including as chairman of the Congressionally-established Diabetes Research Working Group. Dr. Kahn has also served as President of the American Society of Clinical Investigation, and on the Editorial Boards of multiple journals. In 1999, Dr. Kahn was elected to membership in the National Academy of Sciences and the Institute of Medicine for his distinguished achievements in original research. Dr. Kahn also holds honorary Doctor of Science degrees from the University of Paris, University of Louisville and University of Geneva and is an honorary Professor at Peking University School of Medicine.

Grants/Research Support: None

Consulting Fees: Sanofi Aventis, Sirtris/GlaxoSmithKline Pharmaceuticals, FivePrime Therapeutics, Dicerna, Catabasis, CohBar

Speakers' Bureau: None



Lee M. Kaplan, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Director, Obesity, Metabolism & Nutrition Institute
Massachusetts General Hospital

Lee M. Kaplan, MD, PhD, is director of the Obesity, Metabolism & Nutrition Institute and founding director of the Weight Center at the Massachusetts General Hospital and associate professor of medicine at Harvard Medical School. He is the director of the subspecialty fellowship program in Obesity Medicine and Nutrition at MGH, director of the NIH-sponsored Small Animal Metabolic Surgery Core Resource, associate director of the NIH-sponsored Boston-area Nutrition and Obesity Research Center, and Immediate Past Chair of the Campaign to End Obesity.

Dr. Kaplan graduated with honors from Harvard University. He received his M.D. and Ph.D. in molecular biology, both with distinction, from the Albert Einstein College of Medicine. He completed an internship and residency in internal medicine and a fellowship in gastroenterology at the Massachusetts General Hospital and Harvard Medical School and a fellowship in genetics at the Brigham and Women's Hospital.

Dr. Kaplan's clinical expertise is in the areas of obesity medicine, gastroenterology and liver disease. The author of more than 150 medical and scientific papers, he has a special interest in the causes and complications of obesity and the development of new and more effective preventive strategies and therapies for this problem. His clinical research is focused on identifying clinically relevant subtypes of obesity, identifying predictors of outcome of obesity therapies, and exploring novel, combination therapies for obesity and its complications. His basic research is focused on the physiological and molecular mechanisms of gastrointestinal regulation of body weight and metabolic function, and his group has pioneered the development and use of rodent models of weight loss surgery and gastrointestinal devices to explore these mechanisms.

Dr. Kaplan has participated in several obesity advisory panels, including as chair of the American Gastroenterology (AGA) obesity task force, the NIH Clinical Obesity Research Panel, member of the bariatric surgery clinical guidelines committees for the AGA and the Endocrine Society, member of and member of the Certification of Obesity Medicine Physicians (COMP) Steering Committee. Dr. Kaplan was director of the recent FDA workshop on Device development for Obesity and Metabolic Diseases. He currently serves as Vice Chair of the Nutrition and Obesity Section of the AGA and Chair-elect of the Bariatric Surgery section of The Obesity Society.

He lives in Wellesley, Massachusetts with his wife Elizabeth and three children, Katharine, Benjamin and Caroline.

Grants/Research Support: None

Consulting Fees: GI Dynamics, Ethicon, Eisai, Vivus, USGI Medical Inc., Zafgen, Rhythm, Pfizer, Novo Nordisk, Fractyl, Gelesis

Speakers' Bureau: None

Ownership Interest/Shareholder: GI Dynamics, Rhythm



Sekar Kathiresan, MD

Associate Professor of Medicine
Harvard Medical School
Director, Preventive Cardiology
Massachusetts General Hospital

Sekar Kathiresan, a clinical cardiologist and human geneticist, is the director of preventive cardiology at Massachusetts General Hospital and a genetics researcher in the Broad Institute's Program in Medical and Population Genetics. Dr. Kathiresan seeks to discover the genes responsible for inter-individual differences in risk for heart attack and use this information to understand biologic mechanisms and to improve preventive cardiac care. His scientific contributions have been four-fold. First, through genetic studies in populations, he and collaborators have discovered 45 gene regions related to risk for heart attack and 95 gene regions related to risk factors for heart attack including blood cholesterol and triglycerides. Second, through genetic studies in families, he has identified a gene responsible for extremely low levels of LDL cholesterol. Third, he has utilized gene variants to show that some means of raising HDL cholesterol may not lower risk for heart attack. Finally, he has identified a panel of gene variants that can be used to assess future risk for heart attack.

Dr. Kathiresan is an associate professor of medicine at Harvard Medical School. He received his B.A. in history and graduated summa cum laude from the University of Pennsylvania in 1992. He received his M.D. from Harvard Medical School in 1997. Kathiresan completed his clinical training in internal medicine and cardiology at MGH. He served as Chief Resident in Internal Medicine at MGH in 2002-2003. Kathiresan pursued research training in cardiovascular genetics through a combined experience at the Framingham Heart Study and the Broad Institute of MIT and Harvard. In 2008, he joined the research faculties of the MGH Cardiovascular Research Center and the MGH Center for Human Genetic Research.

Grants/Research Support: Merck, Pfizer, Celera

Consulting Fees: Regeneron, American Genomics, Catabasis

Speakers' Bureau: None

DISTINGUISHED FACULTY



William E. Kraus, MD
Professor of Medicine
Duke University School of Medicine

William E. Kraus is a physician scientist and Professor in the Division of Cardiology, Department of Medicine at Duke with specific research interests and experience in cellular signaling processes underlying the plasticity of skeletal muscle gene expression, basic mechanisms of skeletal myocyte development and differentiation, and in physical exercise for the treatment of cardiovascular diseases and myopathies. Dr. Kraus is Director for Clinical Research at the Duke Center for Living, a multidisciplinary treatment and research facility dedicated to the primary and secondary prevention of cardiovascular disease. He also functions as Medical Director of the Duke Cardiac Rehabilitation Program. He graduated from Duke Medical School in 1983 followed by an Internal Medicine Residency and Cardiology Fellowship, all at Duke.

Grants/Research Support: None

Consulting Fees: None

Speakers' Bureau: None



Peter Libby, MD
Mallinckrodt Professor of Medicine
Harvard Medical School
Chief of Cardiovascular Medicine
Brigham and Women's Hospital

Peter Libby, MD, is the Chief of Cardiovascular Medicine at the Brigham and Women's Hospital in Boston, Massachusetts. He also serves as the Mallinckrodt Professor of Medicine at Harvard Medical School. Dr. Libby directs the D.W. Reynolds Cardiovascular Clinical Research Center at Harvard. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has received numerous awards and recognitions for his research accomplishments. His areas of clinical expertise include general and preventive cardiology.

An author and lecturer on cardiovascular medicine and atherosclerosis, Dr. Libby has published extensively in medical journals including *Circulation*, *Journal of Clinical Investigation*, *Proceedings of the National Academy of Sciences*, *New England Journal of Medicine*, and *Nature*. He is Editor-in-Chief of the Eighth edition of *Braunwald's Heart Disease*. Dr. Libby has also contributed the chapter on the pathogenesis, treatment, and prevention of atherosclerosis to *Harrison's Principles of Internal Medicine*. He has held numerous visiting professorships and has been selected to deliver over 60 named or keynote lectures throughout the world.

Dr. Libby's professional memberships include the Association of American Physicians, the American Society for Clinical Investigation, and an honorary membership in the British Atherosclerosis Society. He recently served as the President of the Association of University Cardiologists. He has served in many roles as a volunteer for the American Heart Association, including chairman of several research committees and member of the executive committees of the Councils on Arteriosclerosis, *Circulation*, and Basic Science. He has frequently served as a consultant to the National Heart, Lung, and Blood Institute (NHLBI), including a 5-year term on the Board of Scientific Councilors. He was the recipient of a MERIT Award from the NHLBI.

Dr. Libby has a particular interest in public education regarding heart disease, and served as the principal medical advisor to the Emmy Award winning public television documentary series, *The Mysterious Human Heart*. Dr. Libby writes a cardiovascular blog, *Consults-Experts* on the *Front Lines of Medicine*, for the New York Times website (<http://consults.blogs.nytimes.com>). He is also the co-founder of a non-profit organization The International Partnership for Critical Markers of Disease to promote the development, evaluation, and appropriate clinical utilization of biomarkers.

Dr. Libby earned his medical degree at the University of California, San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital (now Brigham and Women's Hospital). He also holds an honorary MA degree from Harvard University, and an honorary doctorate from the University of Lille, France.

Grants/Research Support: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Merck, Novartis, Pfizer, ProNova, Sigma Tau

Consulting Fees: Athera Biotechnologies, Carolus Therapeutics, Interleukin Genetics

Speakers' Bureau: None



Colleen M. Majewski, MD

Assistant Professor of Medicine
Section of Endocrinology, Diabetes, & Metabolism
The University of Chicago Medicine
Endocrinologist
Duchossois Center for Advanced Medicine

Colleen Majewski, MD received her medical degree from Jefferson Medical College of Thomas Jefferson University in Philadelphia, PA. She completed her internship and residency in Internal Medicine at Northwestern in Chicago, IL. She completed a fellowship in both Endocrinology and Hypertension at the University of Chicago. She is certified by the American Board of Internal Medicine with a subspecialty certification in endocrinology. She is also certified as a Specialist in Clinical Hypertension by the American Society of Hypertension.

Her clinical practice focuses on general endocrinology and the treatment and management of hypertension in the setting of diabetes and obesity, and due to abnormalities of the adrenal gland. Dr. Majewski's research interests are in endocrine hypertension, specifically in the area of obesity hypertension, investigating the interaction between the adipocyte and aldosterone in postmenopausal women.

Grants/Research Support: None

Consulting Fees: None

Speakers' Bureau: None



Aldo J. Peixoto, MD

Professor of Medicine (Nephrology)
Yale School of Medicine
Associate Chair for Ambulatory Operations and Quality
Department of Internal Medicine
Clinical Chief, Section of Nephrology
Director, Yale Hypertension Center

Dr. Aldo Peixoto is a graduate of the Federal University of Santa Catarina (Florianopolis, Brazil), received his training in Internal Medicine at the University of Connecticut (Farmington, CT) and completed his Nephrology fellowship at Yale University (New Haven, CT), and joined the faculty of the Section of Nephrology at Yale and the VA Connecticut Healthcare System in 1998. He is presently the Associate Chair for Ambulatory Operations and Quality, the Clinical Chief of Nephrology, and the Director of the Hypertension Center at Yale-New Haven Hospital. His clinical activities include consultative hypertension, general consultative nephrology, and intensive care nephrology. His research interests focus on the interplay between kidney disease and hypertension, including studies on arterial mechanics, hemodynamic monitoring, BP monitoring, methods of delivery of care in hypertension, and the use of renal denervation in resistant hypertension. He is an associate editor of *Blood Pressure Monitoring and NephSAP*, and a member of the editorial boards of the *American Journal of Nephrology*, the *Clinical Journal of the American Society of Nephrology*, the *Brazilian Journal of Nephrology*, and the *Faculty of 1000 PRIME*. He has published more than 90 peer-reviewed articles and book chapters, and is the co-author of a bedside diagnosis book.

Grants/Research Support: None

Consulting Fees: None

Speakers' Bureau: None

DISTINGUISHED FACULTY

**Paul M. Ridker, MD, MPH**

Eugene Braunwald Professor of Medicine
Harvard Medical School
Director, Center for Cardiovascular Disease Prevention
Brigham and Women's Hospital

Dr. Ridker is the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a translational research unit at the Brigham and Women's Hospital in Boston which focuses on the molecular and genetic epidemiology of cardiovascular diseases and on novel strategies for cardiovascular disease detection and prevention.

As a graduate of Brown University, the Harvard Medical School, and the Harvard School of Public Health, Dr. Ridker's primary research brings together classical tools of large-scale, population based epidemiology with emerging genetic and molecular techniques designed to improve our ability to predict and prevent vascular disease. Particular areas of interest involve molecular and genetic determinants of hemostasis, thrombosis, and inflammation with a focus on "predictive medicine", early disease diagnosis, and the underlying causes and prevention of acute coronary syndromes. Dr. Ridker's research efforts are primarily supported by RO1 research grants from the National Heart, Lung, and Blood Institute (NHLBI), a Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation, and through philanthropic research grants from the Leducq Foundation and the Donald W Reynolds Foundation. Dr. Ridker additionally directs an NHLBI-funded institutional National Research Service Award (training grant) in cardiovascular epidemiology at the Brigham and Women's Hospital and Harvard Medical School. Dr. Ridker has been the recipient of both a Clinician Scientist Award (1992-1997) and an Established Investigator Award (1997-2002) from the American Heart Association. A frequent invited lecturer at national and international conferences, Dr. Ridker lists among his honors elected membership into the American Society for Clinical Investigation (ASCI), the American Epidemiological Society (AES), and the American Association of Physicians (AAP). Citing his pioneering work on inflammation, CRP, and atherothrombosis, Time Magazine honored Dr. Ridker as one of America's Ten Best Researchers in Science and Medicine in 2001 and as one of the "Time 100" in 2004. Dr. Ridker currently serves on the Board of External Experts for the National Heart Lung and Blood Institute. In addition to his work in cardiovascular epidemiology, Dr. Ridker has been the Principal Investigator or Study Chairman of several multinational clinical trials including PREVENT, PRINCE, Val-MARC, LANCET, and the ongoing JUPITER trial evaluating the use of statin therapy among 18,000 apparently healthy individuals with low levels of LDL-C and elevated levels of CRP. Dr. Ridker is also the Principal Investigator of the Women's Genome Health Study (WGHS), a comprehensive prospective genome wide association study being conducted among more than 25,000 initially healthy American women.

Dr. Ridker is the author of over 430 original reports, 140 reviews and book chapters, and 5 textbooks related to cardiovascular medicine. A member of multiple editorial boards, Dr. Ridker is a co-inventor on patents filed by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease.

Grants/Research Support: Novartis, Pfizer, AstraZeneca, Amgen, NHLBI

Consulting Fees: ISIS, Vascular Biogenics, Boston Heart

Speakers' Bureau: None

Royalty/Patent Holder: Co-inventor on patents held by the Brigham and Women's Hospital and licensed to Siemens and AstraZeneca.

**Francesco Rubino, MD**

Professor and Chair of Bariatric and Metabolic Surgery
King's College London, UK

Francesco Rubino, MD is currently Full Professor and Chair of Bariatric and Metabolic Surgery at King's College London, UK.

Dr. Rubino's work contributed to conceptually transform bariatric surgery from a mere weight loss therapy into a surgical approach intentionally aimed at treating diabetes and metabolic illnesses (metabolic surgery). In 1999 Dr. Rubino conceived the idea that gastrointestinal surgery could be used to intentionally treat type 2 diabetes ("diabetes surgery") and theorized that dysfunctional gastrointestinal mechanisms may play a role in the pathophysiology of insulin resistance (Annals of Surgery 2002). His experimental studies in non-obese diabetic rodents provided the first experimental evidence that gastrointestinal surgery can improve diabetes by weight-independent mechanisms (Ann Surg 2004).

Dr. Rubino was also one of the principal organizers of the Rome's Diabetes Surgery Summit in 2007. He also organized and directed the 1st and 2nd World Congress on Interventional Therapies for Type 2 Diabetes and served as a co-chair for the Position Statement of the International Diabetes Federation (IDF) on bariatric surgery for obese diabetes.

His clinical expertise includes laparoscopic bariatric and metabolic procedures, and upper digestive surgery. He has given hundreds of presentations throughout the world, authored or co-authored more than 90 articles in peer-reviewed journals and more than 20 book chapters. His work has also been featured in the media including headlines on national televisions/major newspapers of USA, Japan, Italy, France, UK, Brazil, Ireland, Austria, Qatar, South Africa and other countries.

Dr. Rubino received his MD and completed his residency in general surgery at the Catholic University of Rome, Italy. He completed fellowships in advanced laparoscopic surgery at the European Institute of Telesurgery in Strasbourg, France; Mount Sinai Medical Center, New York and the Cleveland Clinic.

Before joining King's College London, he served at Catholic University of Rome, Italy, Hopital Civil, Strasbourg, France and Weill Cornell Medical College/ New York Presbyterian Hospital in New York, USA.

Grants/Research Support: None

Consulting Fees: NGM Biopharmaceuticals, Fractyl Laboratories

Speakers' Bureau: Covidien



Sidney C. Smith, Jr., MD

Professor of Medicine and Director
Center for Cardiovascular Science and Medicine
The University of North Carolina in Chapel Hill

Sidney C. Smith, Jr., M.D., FAHA, FACC, FESC, FJCS (Hon.) is Professor of Medicine and Director of the Center for Cardiovascular Science and Medicine at the University of North Carolina in Chapel Hill. Dr Smith received his medical degree from Yale Medical School and completed his medical internship, residency, and cardiology fellowship at the Peter Bent Brigham (now Brigham and Women's) Hospital/Harvard Medical School in Boston, MA.

Dr. Smith is a past president of the American Heart Association (AHA) a past member of the AHA Scientific Advisory Board and AHA Board of Directors, and has served as the Chief Science Officer for the AHA. He chaired the ACC/AHA guideline committee to revise PCI guidelines, served on the committee on guidelines for the management of acute myocardial infarction (STEMI), chaired the AHA/ACC Guidelines on Secondary Prevention for patients with atherosclerotic vascular disease and served as chair of the ACC/AHA Task Force on Practice Guidelines. He was Co-Chair of the ACC/AHA Bethesda Conference on Professionalism and Ethics. Dr. Smith is currently the Immediate Past President of the World Heart Federation (WHF) and prior to his presidency of WHF he served as chair of the WHF Scientific Advisory Board. He is currently serving as Chair of the Executive Committee for the National Heart, Lung and Blood Institute of the National Institutes of Health sponsored Integrated Guidelines for the prevention of cardiovascular disease.

Dr. Smith has been elected to fellow status in a number of associations including the American Heart Association, American College of Physicians, American College of Cardiology, European Society of Cardiology, and Royal Society of Medicine. Among his many honors include the American Heart Association's Physician of the Year Award, Distinguished National Leadership Award, Gold Heart Award, and Eugene Drake Award; the Joseph Stokes Award in Preventive Cardiology, and the NHLBI/NIH Award of Special Recognition.

Dr. Smith has authored or co-authored more than 350 published papers and chapters and has served on the editorial boards for the *Journal of Cardiovascular Medicine*, *Journal of Clinical and Experimental Cardiology*, *Journal of the American College of Cardiology* and *Circulation*.

Grants/Research Support: None

Consulting Fees: None

Speakers' Bureau: None



Virend K. Somers, MD, PhD

Professor of Medicine
Mayo Clinic
Consultant in Cardiovascular Diseases
Mayo Clinic and Mayo Foundation

Virend Kristen Somers received his Medicine degree from the University of Natal in South Africa. He was then awarded a Nuffield Dominion Scholarship to Oxford University where he received his Doctor of Philosophy Degree. He subsequently completed a Post-Doctoral Fellowship, Internal Medicine Residency and Cardiology Fellowship at the University of Iowa, where he served as Director of the Cardiovascular Neurophysiology Laboratory. He is presently Professor of Medicine at the Mayo Clinic, and has been appointed as a Mayo Foundation Clinical Investigator. He is Board Certified in Cardiovascular Diseases and is an American Society of Hypertension certified Consultant in Hypertension.

Dr. Somers is a prior Sleep Academic Awardee of the NIH, a Fellow and Established Investigator of the American Heart Association, was elected to the American Society of Clinical Investigation in 1999, and was twice awarded the Demuth Prize for excellence and originality in hypertension research by the International Society of Hypertension. He received the First Prize of the National Young Investigator Competition of the Heart Institute for Children, the Courmand and Comroe Young Investigator Award from the American Heart Association, the David Amar Medal, the Malherbe Distinguished Achievement Award, the American Society of Hypertension Young Scholar Award and the University of Iowa Cardiovascular Division Distinguished Alumnus Award. He was awarded a Doctor Honoris Causa by Masaryk University in the Czech Republic, received the University of Iowa Carver College of Medicine Distinguished Alumnus Early Achievement Award, and was appointed as the American College of Cardiology-Pfizer Visiting Professor in 2005 (University of Chicago), 2006 (University of Alabama), and 2007 (University of Cincinnati). He was also named as the 2007 Royal Perth Hospital Visiting Professor. He currently serves on the Editorial Boards of Hypertension and the Italian Heart Journal, and is Associate Editor for Sleep and Associate Editor for Chest. He has also been elected to membership of the Association of University Cardiologists. He chaired the Writing Committee for the AHA/ACC/NIH Scientific Statement on Sleep Apnea and Cardiovascular Disease, was elected to the Steering Committee of the National Sleep Research Network, and received the Mayo Foundation Department of Medicine Outstanding Investigator Award, as well as the Mayo Foundation Department of Medicine Landmark Contribution to the Literature Award. He recently received the University of Iowa Distinguished Cardiovascular Scientist Award, has been named as the 2011 University of Cape Town Bernard Pimstone Lecturer, and an NIH Biomedicine Series Lecturer. He also received the Lifetime Achievement Award from the South African Association of Sleep Medicine, CTSA Mentor of the Year Award for 2012, and 2014 American Physiologic Society Robert M. Berne Distinguished Lectureship Award.

His work examines the mechanisms influencing the brain's regulation of the heart and blood vessels in both health and disease. His research includes sleep and its interaction with circulatory control, as well as the mechanisms linking obesity to heart disease. This research is funded by three NIH R01 grants, the American Heart Association, the Mayo Foundation, and a European Union Joint Grant to Mayo and the ICRC.

Grants/Research Support: Phillips Respironics Foundation

Consulting Fees: ResMed, Pricewaterhouse Coopers, Respicardia, Sorin

Speakers' Bureau: None

Royalty/Patent Holder: Preventice

DISTINGUISHED FACULTY

**P. Gabriel Steg, MD**

Professor, Cardiology Department
Paris Diderot University
Director, Coronary Care Unit
Hospital Bichat-Claude Bernard
Paris, France

Dr Steg has been a Professor of Cardiology at the Université Paris - Diderot, Sorbonne-Paris Cité, since 1994. He is also Professor at the National Heart and Lung Institute, Imperial College, London, UK since 2013. He works as an interventional cardiologist and is Director of the Coronary Care Unit of Hôpital Bichat, a large academic institution affiliated with Assistance Publique-Hôpitaux de Paris, in Paris, France. He is also Director of the "Clinical Research in Atherothrombosis" Research Team, created in 2008 at INSERM U-698, Hôpital Bichat, Paris and a co-coordinator of the Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and REmodeling) affiliated with INSERM, Université Paris Diderot and Assistance Publique - Hôpitaux de Paris. He is chair of the FACT (French Alliance for cardiovascular Clinical Trials) academic research organization, which is a member of the VIGOUR collaboration.

Dr Steg's research interests are in the field of coronary artery disease. He is involved in studies of intervention in acute coronary syndromes, but has also turned his attention to the epidemiology of atherothrombosis and atrial fibrillation. He is a former member of the Board of the French Society of Cardiology. He is an honorary member of the Institut Universitaire de France, a fellow of the European Society of Cardiology, and American College of Cardiology. He received the silver medal of the European Society of Cardiology in 2011.

Dr Steg is currently chairing or co-chairing several large clinical trials or registries, such as REACH, TAO, EURIKA, EUROMAX, REALISE-AF, ODYSSEY-CV Outcomes, VIVIFY, CLARIFY, and THEMIS. He also participates in the leadership of many trials in coronary artery disease, such as PLATO, SIGNIFY, PROTECT, SAVOR-TIMI53, CHAMPION-Phoenix, DAPT, STABILITY, SOLID-TIMI52 and PEGASUS. He is co-chair of the GRACE registry publication committee. He was DSMB or CEC member or chair for several large trials. Dr Steg has authored more than 600 articles in peer-reviewed international journals, and is a member of the editorial board for *Circulation*, *Circulation: Cardiovascular Interventions*, and the *European Heart Journal*. He is the Editor-in-Chief of the french edition of *Theheart.org* and Editor-in-Chief for *Medscape France*. Finally, Dr Steg was co-chair of the ESC task force in charge of the 2012 Guidelines for management of ST-segment elevation myocardial infarction.

Grants/Research Support: Servier, Sanofi

Consulting Fees: Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo-Lilly, GlaxoSmithKline, Medtronic, Merck-Sharp Dohme, Novartis, Otsuka, Pfizer, Sanofi, Servier, The Medicines Company, Vivus

Speakers' Bureau: None

Ownership Interest/Shareholder: Aterovax

**Neil J. Stone, MD**

Bonow Professor of Medicine
Feinberg School of Medicine, Northwestern University
Suzanne and Milton Davidson Distinguished Physician
Medical Director Vascular Center of the Bluhm Cardiovascular Institute
Northwestern Memorial Hospital

Dr. Neil J. Stone is the Bonow Professor of Medicine in Preventive Cardiology at the Feinberg School of Medicine of Northwestern University. He has a practice in cardiovascular diseases and a special clinic for the diagnosis and management of lipid-related disorders at the Northwestern Medical Faculty Foundation. He is currently the Suzanne and Milton Davidson Distinguished Physician at Northwestern Memorial where he serves as the Medical Director of the Vascular Center for the Bluhm Cardiovascular Institute.

He is a Master of the American College of Physicians (MACP) and a Fellow of the American College of Cardiology (FACC) and the American Heart Association. (FAHA) A founding member of the National Lipid Association (NLA), he is a Fellow of the NLA, a diplomate of the American Board of Clinical Lipidology and serves as an Associates Editor of the *Journal of Clinical Lipidology*.

Dr. Stone was a member of the first and third National Cholesterol Education Program Adult Treatment Panels. (ATP I, III) He is currently the Chair of the Adult Treatment Panel Guideline IV of the National Heart, Lung, Blood Institute.

He is a past Chairman of the American Heart Association (AHA) Nutrition Committee and Clinical Affairs Committee. As part of the AHA Expert Panel on Population and Prevention Science, he participated in the writing groups that published the AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. He was selected to be a writing group member for the revision of the 2004 Evidence-Based Guidelines for Cardio-vascular Disease Prevention in Women as well as the AHA/ADA Statement on Primary Prevention of CVD in Diabetes.

Dr. Stone has co-authored three books on cardiovascular nutrition and/or management of lipid disorders and has authored over 130 publications in this field. The seventh edition of his most recent book, *Management of Lipids in Clinical Practice*, with colleague Conrad Blum M.D. was published in 2008.

Dr. Stone received his medical degree (summa cum laude) from the Feinberg School of Medicine of Northwestern University and completed a fellowship in cardiovascular diseases at that institution. In between he was an intern and resident in Boston at the Brigham and Women's Hospital and then spent three years at the National Institutes of Health under Drs. Fredrickson and Levy.

He was awarded the 2001 Outstanding Volunteer Clinical Teacher Award of the American College of Physicians. In 2002, he was awarded by the senior class of the Feinberg School of Medicine of Northwestern University, the New Jersey Healthcare Foundation Humanism in Medicine Award.

Grants/Research Support: None

Consulting Fees: None

Speakers' Bureau: None



Peter J. Turnbaugh, PhD

Assistant Professor
Department of Microbiology & Immunology
G.W. Hooper Research Foundation
University of California, San Francisco

Peter J. Turnbaugh, Ph.D. is an Assistant Professor, Department of Microbiology and Immunology with the G.W. Hooper Research Foundation at the University of California, San Francisco. He is formerly a Bauer Fellow in the FAS Center for Systems Biology at Harvard University. Since 2004, his research has focused on the metabolic activities performed by the trillions of microbes that colonize our adult bodies. Turnbaugh and his research group combine metagenomics and gnotobiotics (germ-free and intentionally-colonized mice) to study the impact of the gut microbiome on nutrition and drug metabolism. He received a B.A. in Biochemistry, Biophysics, and Molecular Biology from Whitman College and a Ph.D. in microbial genomics from Washington University in Saint Louis.

Grants/Research Support: None

Consulting Fees: None

Speakers' Bureau: None



Thomas A. Wadden, PhD

Professor of Psychology, Department of Psychiatry
Perelman School of Medicine
University of Pennsylvania
Director, Center for Weight and Eating Disorders

Thomas A. Wadden, Ph.D., is the Albert J. Stunkard Professor of Psychology in Psychiatry at the Perelman School of Medicine at the University of Pennsylvania, where he also is Director of the Center for Weight and Eating Disorders. He received his A.B. in 1975 from Brown University and his doctorate in clinical psychology in 1981 from the University of North Carolina at Chapel Hill.

Dr. Wadden's principal research is on the treatment of obesity by methods that have included lifestyle modification, physical activity, very-low-calorie diets, medication, and surgery. He also has investigated the metabolic and behavioral consequences of obesity and weight loss. He has published over 300 scientific papers and book chapters, and co-edited six books, the most recent of which is *Obesity and Its Associated Eating Disorders: A Guide for Mental Health Practitioners* (with Terrence Wilson, Albert Stunkard and Robert Berkowitz). His research has been supported for nearly 30 years by grants from the National Institutes of Health (NIH).

Dr. Wadden is past President of the Obesity Society and past associate editor of the journal, *Obesity*, published by the society. He has served on several NIH panels, including study sections, the Task Force on the Prevention and Treatment of Obesity, and the Obesity Clinical Guidelines Committee. He also has served as a consultant to the Department of Veteran's Affairs, the Federal Trade Commission, and the Institute of Medicine. His research has been recognized by several awards, including the George Bray Founders Award and the TOPS Research Award, both from The Obesity Society.

Grants/Research Support: Novo Nordisk, Weight Watchers

Consulting Fees: Novo Nordisk, Nutrisystem, Orexigen

Speakers' Bureau: None



Matthew R. Weir, MD

Professor and Director
Division of Nephrology
University of Maryland School of Medicine

Matthew R. Weir, MD, is attending physician and Director of the Division of Nephrology in the Department of Medicine at the University of Maryland Hospital, Baltimore. He is also Professor of Medicine at the University of Maryland School Of Medicine.

Dr. Weir's primary research interests include the use of antihypertensive therapy for the treatment of diabetic nephropathy, hypertensive renal injury in African Americans, and preventing allograft nephropathy in transplant recipients. He has written more than 500 manuscripts and book chapters about these topics. He has edited five books including "Medical Management of Kidney Transplantation" and "Hypertension". He has presented at numerous international scientific association meetings, hospitals, and medical schools.

Dr. Weir currently reviews manuscripts for more than 30 major medical journals, including the *American Journal of Kidney Disease*, the *Journal of the American Society of Nephrology*, and *Archives of Internal Medicine*. He is on the editorial board of ten journals and is Section Editor of Current Hypertension Reports and Current Opinion in Hypertension and Nephrology, and Associate Editor of Clinical Nephrology and the American Journal of Nephrology. He has two active NIH supported grants from NIDDK. In addition, he is a member of numerous associations, including the American Society of Nephrology, the National Kidney Foundation, the American Heart Association, and the American Society of Transplantation.

Dr. Weir received his medical degree from the University of Virginia, Charlottesville. He completed his internship and residency programs in medicine at the Waterbury and Yale-New Haven Hospitals in Connecticut, and completed his nephrology training at the Brigham and Women's Hospital, Harvard Medical School, in Boston, Massachusetts. He then moved to the University of Maryland where he has been a full time faculty member since 1983.

Grants/Research Support: None

Consulting Fees: Keryx, Amgen, Janssen, Relypsa, Otsuka, Sandoz, Bristol-Myers Squibb

Speakers' Bureau: None

SAVE THE DATE!



10TH ANNUAL

Cardiometabolic Health Congress

October 21 - 24, 2015 • Boston, MA

Visit **www.cmhc-online.com** to
access video recordings from
CMHC symposia & online CME/CE activities.

Tel: 732.758.0030 • Fax: 866.218.9168 • E-mail: info@cardiometabolicealth.org
www.cardiometabolicealth.org